fbpx > Skip to main content

Vivos Therapeutics to Participate at the Q1 Virtual Investor Summit

Vivos management to present at 1:30 pm Eastern Time on March 23, 2021

HIGHLANDS RANCH
Colorado, March 1, 2021

HIGHLANDS RANCH, Colo., March 11, 2021 – Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that Kirk Huntsman, Chief Executive Officer, Brad Amman, Chief Financial Officer and Ed Loew, Investor Relations Officer, will be presenting at the Q1 Virtual Investor Summit at 1:30 pm EST on March 23, 2021.

Vivos Therapeutics, Inc. will be presenting at the conference on Tuesday, March 23, 2021 at 1:30 pm Eastern Time.  Investors interested in joining the Vivos presentation can register at the link below:

Register to Attend This Event

Register to Attend

A replay of the presentation will be available for view following the presentation on Vivos’ website after the event.

About Vivos Therapeutics, Inc.

Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea (OSA).  Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Combining technologies and protocols that alter the size, shape and position of the tissues of the upper human airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA.  The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA.  Sales of the Vivos System are driven by the Vivos Integrated Practice (VIP) program, which offers dentists training and value-added services in connection with their use of the Vivos System.

About The Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting small-cap and micro-cap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors.

Cautionary Note Regarding Forward-Looking Statements 

This press release contains “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein.  Words such as “may”, “should”, “expects”, “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements.  These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including, without limitation, the market acceptance of the new software described herein and the impact of the new software on Vivos’ results of operations) may differ materially from those expressed or implied by such forward-looking statements.  Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov.  Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Investor Relations Contact:

Edward Loew
Investor Relations Officer
(602) 903-0095
[email protected]

Media Relations Contact:

Caitlin Kasunich / Jenny Robles
KCSA Strategic Communications
(212) 896-1241 / (917) 420-1444
[email protected] / [email protected]